Multidrug Resistance Proteins in Patients Enrolled in Clinical Trials Outside of the National Cancer Institute Center for Cancer Research

Status:	Archived
Conditions:	Breast Cancer, Cancer, Cancer, Brain Cancer
Therapuetic Areas:	Oncology
Healthy:	No
Age Range:	Any
Updated:	7/1/2011
Start Date:	December 2005

Multidrug Resistance Molecular Target Analysis of Human Samples Collected in Clinical Trials Performed Outside of the Intramural National Cancer Institute

RATIONALE: Studying samples of tumor tissue or blood from patients with cancer in the
laboratory may help doctors learn more about cancer and the development of multidrug
resistance in patients.

PURPOSE: This laboratory study is looking at multidrug resistance proteins in patients
enrolled in clinical trials outside of the National Cancer Institute Center for Cancer
Research.

OBJECTIVES:

- Determine expression of MDR-1 gene/P-glycoprotein and related drug resistance proteins
in tumor tissue samples from patients enrolled in clinical trials outside of the
National Cancer Institute Center for Cancer Research.

OUTLINE: Tumor tissue or blood samples that have been previously collected from patients are
analyzed for P-glycoprotein and other multidrug transporters (e.g., MRP-1 and ABCG2) by
immunohistochemistry, microarray analysis, and reverse transcriptase-polymerase chain
reaction.

The identity of individual patients remains confidential. No results of sample analyses are
provided to patients or family members.

PROJECTED ACCRUAL: An unlimited number of patient samples will be accrued for this study.

We found this trial at

sites

Arizona Clinical Research Center, Inc.

Tucson, Arizona 85715

from

Tucson, AZ